We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks.
- Authors
Pfestroff, A.; Luster, M.; Jilg, C.; Olbert, P.; Ohlmann, C.; Lassmann, M.; Maecke, H.; Ezziddin, S.; Bodei, L.
- Abstract
The authors reflect on the current status and future perspectives of prostate-specific membrane antigen (PSMA)-targeted therapy for prostate cancer (PCA) in Europe. Topics discussed include the pevalence of the disease in Europe, the progression in castration-resistant PCA (CRPC), and a list of compounds approved for the treatment of CRPC such as docetaxel and cabazitaxel after docetaxel.
- Subjects
PROSTATE-specific membrane antigen; TUMOR antigens; PROSTATE cancer treatment; CANCER treatment; DOCETAXEL; THERAPEUTICS
- Publication
European Journal of Nuclear Medicine & Molecular Imaging, 2015, Vol 42, Issue 13, p1971
- ISSN
1619-7070
- Publication type
Editorial
- DOI
10.1007/s00259-015-3186-3